Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
TIA
MCID: TRN015
MIFTS: 62

Transient Cerebral Ischemia (TIA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Transient Cerebral Ischemia

About this section

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 55 15 72
Transient Ischemic Attack 12 54 55 6 43 17 72
Transient Ischemic Attacks 12 15
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia 12
Ischemic Attack, Transient 44
Tia 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Neuronal diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:224
MeSH 44 D002546
NCIt 50 C50781
SNOMED-CT 68 38609002
ICD10 33 G45.9
UMLS 72 C0007787 C0917805
Sources

Summaries for Transient Cerebral Ischemia

About this section
MedlinePlus : 43 A transient ischemic attack (TIA) is a stroke that lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and carotid artery occlusion, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Transient Cerebral Ischemia is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are G-protein signaling Ras family GTPases in kinase cascades (scheme) and Toxoplasmosis. The drugs Aspirin and Irbesartan have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotype is nervous system.

Disease Ontology : 12 A brain ischemia that is characterized by ischemia of brief duration and without resultant tissue death.

NINDS : 54 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 75 A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by loss of blood... more...

Sources

Related Diseases for Transient Cerebral Ischemia

About this section

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 458)
# Related Disease Score Top Affiliating Genes
1 ischemia 30.9 MAP2 HSPA4 HSPA1A CASP3
2 carotid artery occlusion 30.0 MAP2 HSPA1A APOH
3 cytomegalovirus infection 29.9 IL1B CCL2 CASP3
4 spinal cord infarction 29.4 MTHFR APOH
5 placenta disease 29.0 MTHFR IL1B APOH
6 intracranial hypertension 29.0 MTHFR IL1B APOH
7 migraine with or without aura 1 28.3 NOTCH3 MTHFR APOH
8 stroke, ischemic 27.2 NOTCH3 MTHFR MAP2 HSPA4 CASP3 APOH
9 mini stroke 11.9
10 vertebrobasilar insufficiency 11.7
11 paresthesia 11.7
12 essential thrombocythemia 11.7
13 moyamoya disease 1 11.7
14 carotid artery disease 11.7
15 sneddon syndrome 11.5
16 moyamoya disease 2 11.5
17 moyamoya disease 6 with or without achalasia 11.5
18 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.4
19 buerger disease 11.4
20 telangiectasia, hereditary hemorrhagic, type 4 11.4
21 moyamoya disease 5 11.4
22 aganglionosis, total intestinal 11.3
23 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 11.2
24 cerebral artery occlusion 10.8
25 arteries, anomalies of 10.5
26 atrial fibrillation 10.5
27 brain edema 10.4
28 thrombocytosis 10.3
29 cardiac arrest 10.3
30 ataxia and polyneuropathy, adult-onset 10.3
31 papilledema 10.3
32 intermediate coronary syndrome 10.3
33 sickle cell disease 10.3
34 sleep apnea 10.3
35 hyperglycemia 10.2
36 purulent labyrinthitis 10.2 IL1B CCL2
37 meningitis 10.2
38 thrombophilia due to thrombin defect 10.2
39 peripheral vascular disease 10.2
40 pure autonomic failure 10.2
41 headache 10.2
42 mesenteric vascular occlusion 10.2 ODC1 MTHFR
43 hydrops, lactic acidosis, and sideroblastic anemia 10.2
44 apnea, obstructive sleep 10.2
45 atrial standstill 1 10.2
46 hemiplegia 10.2
47 heart septal defect 10.2
48 brain stem infarction 10.2
49 kidney disease 10.2
50 chronic kidney disease 10.2

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (show top 50) (show all 86)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Maxillary Sinusitis
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Kidney Disease Labyrinthitis
Left Bundle Branch Hemiblock Macular Degeneration, Age-Related, 1
Major Depressive Disorder Malignant Essential Hypertension

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia
Sources

Symptoms & Phenotypes for Transient Cerebral Ischemia

About this section

UMLS symptoms related to Transient Cerebral Ischemia:


seizures, tremor, angina pectoris, edema, chest pain, back pain, amaurosis fugax, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Transient Cerebral Ischemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 BAD CASP3 DRD1 GRIN2A HSPA4 IL1B
Sources

Drugs & Therapeutics for Transient Cerebral Ischemia

About this section

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
5
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
6
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
9
Nicotine Approved Phase 4 54-11-5 942 89594
10
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
11
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Metformin Approved Phase 4 657-24-9 4091 14219
14
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
15
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
16
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
17
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
18
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Tranexamic Acid Approved Phase 4 1197-18-8 5526
21
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
24
Allopurinol Approved Phase 4 315-30-0 2094
25
Losartan Approved Phase 4 114798-26-4 3961
26
Pravastatin Approved Phase 4 81093-37-0 54687
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
29
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
30
Ethanol Approved Phase 4 64-17-5 702
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
33
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
34
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
35
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
36
Candesartan Experimental Phase 4 139481-59-7 2541
37
Dabigatran Investigational Phase 4 211914-51-1
38 3-n-butylphthalide Phase 4
39 Neuroprotective Agents Phase 4
40 Prasugrel hydrochloride Phase 4 389574-19-0
41 Radiation-Protective Agents Phase 4
42 Sildenafil Citrate Phase 4 171599-83-0
43 Citrate Phase 4
44 Phosphodiesterase 5 Inhibitors Phase 4
45 Vardenafil Dihydrochloride Phase 4
46 Vitamins Phase 4
47 Vitamin B Complex Phase 4
48 Vitamin B9 Phase 4
49 Folate Phase 4
50 Micronutrients Phase 4

Interventional clinical trials:

(show top 50) (show all 464)
# Name Status NCT ID Phase Drugs
1 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
2 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
3 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
4 The Impact of Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Evaluated by Computed Tomography Perfusion (CTP) Unknown status NCT02594800 Phase 4 Rosuvastatin
5 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
6 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
7 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
8 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
9 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
10 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
11 CRYptogenic STroke And underLying AF Trial Completed NCT00924638 Phase 4
12 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
13 A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke Completed NCT00147602 Phase 4 atorvastatin
14 Preventing Recurrent Vascular Events and Neurological Worsening Through Intensive Organized Case-Management (PREVENTION) Trial Completed NCT00931788 Phase 4 Antihypertensive agents and lipid lowering therapy
15 Efficacy and Cost-effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease Completed NCT00962988 Phase 4 Cost-Free Pharmacotherapy Group
16 The Effect of Dipyridamole on the Pharmacokinetics of Metformin Completed NCT01613755 Phase 4 Metformin, dipyridamole;Metformin
17 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
18 Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) Completed NCT00454662 Phase 4 olmesartan medoxomil / amlodipine or azelnidipine;olmesartan medoxomil / low dose thiazide type drug
19 The Ischemia Management With Accupril Post Bypass Graft Via Inhibition of the coNverting Enzyme (IMAGINE) Trial Completed NCT00269243 Phase 4 Quinapril
20 A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial Completed NCT00340314 Phase 4 Antiarrhythmic Drug Therapy
21 Efficacy of Different Perioperative Statin Regimens on the Protection Against Post Coronary Artery Bypass Grafting Major Adverse Cardio-cerebral Events Completed NCT02706860 Phase 4 Atorvastatin
22 Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy Completed NCT00916643 Phase 4
23 Determining the Optimal Dose of Tranexamic Acid in Decreasing Blood Loss During Lower Extremity Total Joint Arthroplasty Completed NCT02584725 Phase 4 Tranexamic Acid
24 Multiple Intervention and AUdit in Renal Diseases to Optimize Care: the MAURO Study. Completed NCT00566033 Phase 4
25 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
26 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
27 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
28 Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack Recruiting NCT02122718 Phase 4 Allopurinol;Placebo
29 Efficacy of Two Different Doses of Atorvastatin for Prevention of Periprocedural Ischemic Brain Damage in Chinese Patients Undergoing Carotid Artery Stenting (CAS) Recruiting NCT03079115 Phase 4 High-dose Atorvastatin;Conventional-dose Atorvastatin
30 Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD Recruiting NCT03417388 Phase 4 High dose potent statin;ACE-I (lisinopril) or ARB (losartan);Aspirin
31 European Society of Hypertension and Chinese Hypertension League Stroke in Hypertension Optimal Treatment Trial Recruiting NCT01563731 Phase 4 all approved antihypertensive drugs; all approved statins
32 Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE Recruiting NCT03566667 Phase 4 Metoprolol;Standard care
33 Influenza Vaccination After Myocardial Infarction (IAMI Trial): A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the Swedish Angiography and Angioplasty Registry (SCAAR) Platform Recruiting NCT02831608 Phase 4
34 Use of Rosuvastatin to Achieve Lipid Targets in African American Subjects With Cerebrovascular Disease Terminated NCT01975194 Phase 4 Rosuvastatin
35 Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery Terminated NCT01837069 Phase 4 Metoprolol;Lisinopril;Atorvastatin
36 Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging Terminated NCT02114697 Phase 4 Statin therapy
37 Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation Terminated NCT01546883 Phase 4 Dabigatran etexilate (Pradaxa)
38 Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients: A Randomized Control Trial Withdrawn NCT00390247 Phase 4 thalidomide
39 A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Unknown status NCT00201461 Phase 2, Phase 3 Best medical therapy
40 Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design Unknown status NCT02221102 Phase 2, Phase 3 Aspirin;edoxaban;placebo
41 Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke Unknown status NCT01923818 Phase 2, Phase 3 rivaroxaban;Aspirin;placebo
42 A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During Transcatheter Aortic Valve Implantation (TAVI) OperationS - the PTOLEMAIOS Study. Unknown status NCT02989558 Phase 3 Ticagrelor plus ASA;Clopidogrel plus ASA
43 SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke Completed NCT00061022 Phase 3 NXY-059
44 Comprehensive Cardiac Rehabilitation Programming For Patients Following Transient Ischemic Attack Completed NCT00536562 Phase 3
45 Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease Completed NCT00984308 Phase 2, Phase 3
46 Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZâ„¢ and the EndoTexâ„¢ NexStentâ„¢ Completed NCT00600327 Phase 3
47 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation Completed NCT02283294 Phase 3 Apixaban;Warfarin
48 Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery Completed NCT00235248 Phase 3 Warfarin;Clopidogrel-aspirin
49 Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis Completed NCT00190398 Phase 3
50 Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) Completed NCT00109382 Phase 2, Phase 3 Aspirin;Clopidogrel;Simvastatin

Search NIH Clinical Center for Transient Cerebral Ischemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acenocoumarol
Acetylsalicylic acid
Pravastatin

Cochrane evidence based reviews: ischemic attack, transient

Sources

Genetic Tests for Transient Cerebral Ischemia

About this section
Sources

Anatomical Context for Transient Cerebral Ischemia

About this section

MalaCards organs/tissues related to Transient Cerebral Ischemia:

41
Brain, Heart, Testes, Eye, Endothelial, Kidney, Spinal Cord
Sources

Publications for Transient Cerebral Ischemia

About this section

Articles related to Transient Cerebral Ischemia:

(show top 50) (show all 8961)
# Title Authors PMID Year
1
Japanese Versus Non-Japanese Patients with Transient Ischemic Attack or Minor Stroke: Subanalysis of TIA registry.org. 38 17
31178360 2019
2
Intracranial Artery Calcium Burden Predicts Recurrent Cerebrovascular Events in Transient Ischaemic Attack Patients. 17
31204203 2019
3
Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. 17
31171523 2019
4
Ischemia-related changes in naive and mutant forms of ubiquitin and neuroprotective effects of ubiquitin in the hippocampus following experimental transient ischemic damage. 9 38
19666022 2009
5
Cerebral ischemia/stroke and small ubiquitin-like modifier (SUMO) conjugation--a new target for therapeutic intervention? 9 38
18410505 2008
6
Postischemic alterations of BDNF, NGF, HSP 70 and ubiquitin immunoreactivity in the gerbil hippocampus: pharmacological approach. 9 38
16810563 2007
7
Transient cerebral ischemia induces delayed proapoptotic Bad translocation to mitochondria in CA1 sector of hippocampus. 9 38
15710244 2005
8
Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. 9 38
14764933 2004
9
Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia. 9 38
14580322 2003
10
Differential expression of HSC73 and HSP72 mRNA and proteins between young and adult gerbils after transient cerebral ischemia: relation to neuronal vulnerability. 9 38
10908039 2000
11
Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. 9 38
10686447 2000
12
Immunoelectron microscopic study of c-Fos, c-Jun and heat shock protein after transient cerebral ischemia in gerbils. 9 38
9930891 1999
13
Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. 9 38
9774747 1998
14
677C to T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and plasma homocyst(e)ine levels in patients with TIA or minor stroke. 9 38
9562260 1998
15
Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. 9 38
8841320 1996
16
Disturbances of calcium homeostasis within the endoplasmic reticulum may contribute to the development of ischemic-cell damage. 9 38
8910877 1996
17
Induction of c-fos and c-jun gene products and heat shock protein after brief and prolonged cerebral ischemia in gerbils. 9 38
7660411 1995
18
Blockade of ornithine decarboxylase enzyme protects against ischemic brain damage. 9 38
7929646 1994
19
Coexpression of c-fos and hsp70 mRNAs in gerbil brain after ischemia: induction threshold, distribution and time course evaluated by in situ hybridization. 9 38
7854054 1994
20
An immunohistochemical study of parvalbumin containing interneurons in the gerbil hippocampus after cerebral ischemia. 9 38
7838065 1994
21
Delayed damage of striatal interneurons after cerebral ischemia in the gerbil. 9 38
7970228 1994
22
Hemostatic markers in acute transient ischemic attacks. 9 38
8303732 1994
23
[Induction of HSP70 and neuronal damage following transient cerebral ischemia in rats]. 9 38
8239864 1993
24
Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. 9 38
8417138 1993
25
Autoradiographic analysis of dopamine D1 receptors in the gerbil brain following transient cerebral ischemia. 9 38
1487117 1992
26
Calcium/calmodulin dependent protein kinase II mRNA in the gerbil brain after cerebral ischemia. 9 38
1331917 1992
27
Activity of ornithine decarboxylase and S-adenosylmethionine decarboxylase in transient cerebral ischemia: relationship to the duration of vascular occlusion. 9 38
1499693 1992
28
Hyperglycemia suppresses c-fos mRNA expression following transient cerebral ischemia in gerbils. 9 38
1727138 1992
29
Postischemic alteration of muscarinic acetylcholine and adenosine A1 binding sites in gerbil brain. Protective effects of a novel vinca alkaloid derivative, vinconate, and pentobarbital using an autoradiographic study. 9 38
1529167 1992
30
Mild hypothermia ameliorates ubiquitin synthesis and prevents delayed neuronal death in the gerbil hippocampus. 9 38
1660190 1991
31
Postischemic alteration of muscarinic acetylcholine, adenosine A1 and calcium antagonist binding sites in selectively vulnerable areas: an autoradiographic study of gerbil brain. 9 38
1666408 1991
32
An immunohistochemical study of MAP2 and clathrin in gerbil hippocampus after cerebral ischemia. 9 38
1722131 1991
33
Clinical efficacy and safety of statin treatment after carotid artery stenting. 38
31352800 2019
34
Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. 38
31237713 2019
35
Nestorone exerts long-term neuroprotective effects against transient focal cerebral ischemia in adult male rats. 38
30244019 2019
36
Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: from the US payer perspective. 38
31025589 2019
37
Application of Neck Circumference in Four-Variable Screening Tool for Early Prediction of Obstructive Sleep Apnea in Acute Ischemic Stroke Patients. 38
31296477 2019
38
Acute remote ischemic preconditioning alleviates free radical injury and inflammatory response in cerebral ischemia/reperfusion rats. 38
31410157 2019
39
Temporal Trends of Sex Differences in Transient Ischemic Attack Incidence Within a Population. 38
31270019 2019
40
High-resolution diffusion-weighted imaging identifies ischemic lesions in a majority of transient ischemic attack patients. 38
31298762 2019
41
Achievement of target SBP without attention to decrease in DBP can increase cardiovascular morbidity in treated arterial hypertension: the Campania Salute Network. 38
31205199 2019
42
Validation of a multivariate clinical prediction model for the diagnosis of mild stroke/transient ischemic attack in physician first-contact patient settings. 38
29251055 2019
43
Long segment dolichoectasia of the right internal carotid artery diagnosed by CT angiography. 38
31338131 2019
44
Stroke Mimics: An Important Source of Bias in Acute Ischemic Stroke Research. 38
31256984 2019
45
Association Between Carotid-Cerebral Pulse Wave Velocity and Acute Ischemic Stroke: Clinical Trial Protocol. 38
31239221 2019
46
Physical activities attenuate the negative cognitive impact from white matter hyperintensities in stroke and TIA patients with low education. 38
31407822 2019
47
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. 38
31160218 2019
48
Periprocedural complications of second-generation flow diverter treatment using Pipeline Flex for unruptured intracranial aneurysms: a systematic review and meta-analysis. 38
31147438 2019
49
Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study. 38
31421933 2019
50
Association of Smoking Status With Long-Term Mortality and Health Status After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 38
31423877 2019
Sources

Variations for Transient Cerebral Ischemia

About this section

ClinVar genetic disease variations for Transient Cerebral Ischemia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 NOTCH3 NM_000435.3(NOTCH3): c.457C> T (p.Arg153Cys) single nucleotide variant Pathogenic rs797045014 19:15302993-15302993 19:15192182-15192182
2 NOTCH3 NM_000435.3(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic rs1555728965 19:15299088-15299088 19:15188277-15188277
Sources

Expression for Transient Cerebral Ischemia

About this section
Search GEO for disease gene expression data for Transient Cerebral Ischemia.
Sources

Pathways for Transient Cerebral Ischemia

About this section

Pathways related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 11.88 PTK2B MAP2 CCL2 CASP3
2
Toxoplasmosis 37
Show member pathways
 11.83 IL1B HSPA1A CASP3 BAD
3
Spinal Cord Injury 1
11.71 IL1B CCL2 CASP3
4
TNF signaling pathway 37
11.66 IL1B CCL2 CASP3
5
AGE-RAGE signaling pathway in diabetic complications 37
11.54 IL1B CCL2 CASP3
6
Selenium Micronutrient Network 1
Show member pathways
 11.36 MTHFR KYNU KMO IL1B CCL2
7
Amyotrophic lateral sclerosis (ALS) 37 1
Show member pathways
 11.31 SLC1A1 GRIN2A CASP3 BAD
8
Legionellosis 37
11.08 IL1B HSPA1A CASP3
9
LDL Oxidation in Atherogenesis 64
10.61 IL1B CCL2
Sources

GO Terms for Transient Cerebral Ischemia

About this section

Cellular components related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 PTK2B ODC1 NOTCH3 MTHFR MAP2 KYNU
2 NMDA selective glutamate receptor complex GO:0017146 8.96 PTK2B GRIN2A

Biological processes related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.91 IL1B CCL2 CASP3 BAD
2 response to glucose GO:0009749 9.73 PTK2B CASP3 BAD
3 MAPK cascade GO:0000165 9.72 PTK2B IL1B CCL2
4 cellular response to organic cyclic compound GO:0071407 9.71 IL1B CCL2 CASP3
5 response to hydrogen peroxide GO:0042542 9.69 PTK2B CASP3 BAD
6 response to hypoxia GO:0001666 9.65 PTK2B MTHFR CASP3
7 chaperone-mediated protein complex assembly GO:0051131 9.63 HSPA4 HSPA1A
8 long-term synaptic potentiation GO:0060291 9.63 PTK2B GRIN2A DRD1
9 long-term synaptic depression GO:0060292 9.62 PTK2B DRD1
10 response to estradiol GO:0032355 9.62 CASP3 BAD
11 dopamine metabolic process GO:0042417 9.61 GRIN2A DRD1
12 NAD biosynthetic process GO:0009435 9.6 KYNU KMO
13 activation of cysteine-type endopeptidase activity GO:0097202 9.59 GRIN2A BAD
14 pyridine nucleotide biosynthetic process GO:0019363 9.58 KYNU KMO
15 memory GO:0007613 9.58 GRIN2A DRD1
16 cellular response to organic substance GO:0071310 9.58 MAP2 IL1B CASP3
17 tryptophan catabolic process GO:0006569 9.57 KYNU KMO
18 response to amino acid GO:0043200 9.54 MTHFR CASP3 BAD
19 response to glucocorticoid GO:0051384 9.52 CASP3 BAD
20 positive regulation of glucokinase activity GO:0033133 9.49 GCKR BAD
21 'de novo' NAD biosynthetic process from tryptophan GO:0034354 9.43 KYNU KMO
22 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.33 IL1B CASP3 BAD
23 quinolinate biosynthetic process GO:0019805 9.32 KYNU KMO
24 anthranilate metabolic process GO:0043420 9.26 KYNU KMO
25 response to ethanol GO:0045471 9.13 PTK2B GRIN2A BAD
26 response to drug GO:0042493 9.1 PTK2B MTHFR GRIN2A DRD1 CASP3 BAD

Molecular functions related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase activator activity involved in apoptotic process GO:0008656 8.65 BAD
2 NMDA glutamate receptor activity GO:0004972 8.62 PTK2B GRIN2A
Sources

Sources for Transient Cerebral Ischemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....